Elevance Health closed at a fresh one-year high of $446.42, 0.26% above its prior peak set on October 22. Competitor Clover Health slipped 0.2% on the day.
- Dec 31, 2025 · SEC 10-K
Moves: Nov 16, 2026 · Alpha Vantage daily close
2 have no US listing
Headquartered in Wilmington, DE Fiscal year ends December NASDAQ: CLOV cloverhealth.com
Clover Health Investments, Corp. (Nasdaq: CLOV) describes itself as a physician enablement technology company focused on access to healthcare for people on Medicare, including seniors who have historically lacked affordable, high-quality care.
Its operations center on two pieces:
- **Clover Assistant:** a software platform that aggregates patient data from across the healthcare ecosystem. It supports clinical decision-making and the early identification and management of chronic diseases such as diabetes, chronic kidney disease, congestive heart failure and COPD.
- **Insurance:** the company's reporting segment, which offers PPO and HMO Medicare Advantage plans in several states. The emphasis is on its flagship wide-network, high-choice PPO, which holds about 98% of members and received a 5 Star rating for Payment Year 2028.
The Insurance segment generates nearly all revenue through premiums. Through its subsidiary Counterpart Health, Clover licenses its technology to external payors and providers under the Counterpart Assistant brand.
As of September 30, 2026, Clover served 158,907 Medicare Advantage members, up 45% year over year. Updated
Elevance Health closed at a fresh one-year high of $446.42, 0.26% above its prior peak set on October 22. Competitor Clover Health slipped 0.2% on the day.
Moves: Nov 16, 2026 · Alpha Vantage daily close
2 have no US listing
The managed-care name is back at the top of its range.
The 9.05% run came the same day Humana, a competitor, posted Q3 2026 results. Managed care names moved together into the close.
Humana Q3 2026 earnings release
Moves: Nov 6, 4:20 PM ET · Alpha Vantage quote
3 more related stocks · 4 have no US listing
Through Clover Assistant, we are committed to delivering better clinical quality and lower total cost of care. We are pleased that this continues to show up in our results, with ~98% of our members enrolled in our 5 Star rated PPO for Payment Year 2028, alongside our third consecutive year of nation-leading HEDIS performance.
Star ratings are where Medicare Advantage bonus money is won or lost, and while CVS and Aetna fight CMS in court over their downgrades, Clover's CEO says nearly all of its membership sits in a 5-Star plan for Payment Year 2028. That locks in bonus payments at a $2 billion company whose rivals are litigating to protect theirs.
Clover Health is now running a real profit engine, turning a year-ago loss into GAAP net income of $6.4 million. Management raised the low end of every full-year 2026 target and says 2027 open enrollment is tracking well.
Our results further demonstrate our technology-powered differentiation, and how earlier and better care management, market-leading growth, and increasing profitability can reinforce one another under the right model.
Toy is claiming Clover can grow membership and widen margins at the same time, a combination most Medicare Advantage insurers have abandoned as star ratings tighten and costs climb. For a $2 billion insurer, that claim on the Q3 call is the whole investment case, so the proof has to show up in next quarter's medical cost ratio.
General Motors shed 7.5% into the close, the worst showing across 387 priority names and nearly double the next-biggest decline. GoPro and Clover Health anchored the other end, each up more than 7.5%.
An 8.3% slide to $4.72 wipes out the $5 handle on a $2.1 billion insurer, and it lands a day after the stock already shed 6.9%. Back-to-back drops like this reset the base for anyone waiting to buy.
All three major US wireless carriers are at the bottom of the board at the open, with T-Mobile down 8.9% and AT&T and Verizon close behind. Optical names lead the other side, Applied Optoelectronics up 8.9%.
Clover Health is adding boardroom muscle just as CMS and insurers fight over 2027 Medicare Advantage rates, the single variable that decides whether this $1.9 billion insurtech keeps scaling. Board additions at a company this size shift who sets the growth-versus-margin call.
A $0 monthly premium sounds like free coverage until you read the pages most people skip. One number buried in the Annual Notice of Change quietly decides how much a serious diagnosis…
After years of burning cash and testing investor patience, Clover Health just posted results that bulls have been waiting for. But with medical costs creeping up and the stock already priced for…
In this piece, we’ll check in on two mid-cap health insurance plays that are leveraging their tech-savvy and digital strengths to grab a bigger slice of the health insurance industry. Indeed, if…
Chamath Palihapitiya is a prominent venture capitalist, engineer, and entrepreneur known for his significant contributions to the tech sector. Venture capitalists were certainly among the top influencers of the post-pandemic era, when…
While special purpose acquisition companies (SPACs) have been around for years, they really burst onto the mainstream investor’s consciousness in 2020. That year there was an explosion of so-called “blank check” company…
Here is a look at one company set to report quarterly results before markets open Wednesday and three more on deck for after the markets close.
Wednesday afternoon's top analyst upgrades and downgrades included Advanced Micro Devices, Clorox, Clover Health Investments, Datadog, Electronic Arts, Etsy, General Motors, Intuitive Surgical, Starbucks and Under Armour.
EV stocks weren't the only equities to get pasted Thursday. Marijuana growers took a hit as well, but there may be some good news from Europe Friday morning.
Nearly every electric vehicle stock traded lower Thursday, as investors likely were pocketing some profits on the recent runup in these stocks.
One stock that had its moment in the meme stock sun last January has been generating some chatter lately among some retail investors.
Retail investors have some choice short squeeze targets this week and one stock, in particular, could see continued heavy volume and volatility.
Markets have been muted today with most sectors traded lower. Meme stock moves as of noon Friday have followed the same script, but the day is still young.
Thursday was mostly an up-day for meme stocks and Friday may be shaping up for more of the same.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
Meme stocksweare lining up with the major indexes and trending lower at midday on Wednesday.
Clover Health Investments, Corp. (Nasdaq: CLOV) describes itself as a physician enablement technology company focused on access to healthcare for people on Medicare, including seniors who have historically lacked affordable, high-quality care.
The Wall Street consensus 12-month price target for CLOV is $5.60.